Schlusskurs
Andere Börsenplätze
|
||
- USD | - |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | - |
Chief Operating Officer | - | 01.06.18 | |
Steven Klayman
PRN | Corporate Officer/Principal | - | - |
Mostafa Abuzeid
PRN | Corporate Officer/Principal | - | - |
Hans Christinger
PRN | Corporate Officer/Principal | - | - |
Gilbert Jaoudé
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 3 204 401 | 2 483 540 ( 77,50 %) | 0 | 77,50 % |
Unternehmenskontakt
Innovus Pharmaceuticals, Inc.
373 Inverness Parkway Suite 206
80112, Englewood
+858-964-5123
http://www.innovuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+38,51 % | 728 Mrd. | |
+33,05 % | 603 Mrd. | |
-6,23 % | 360 Mrd. | |
+18,78 % | 332 Mrd. | |
+1,35 % | 279 Mrd. | |
+16,00 % | 244 Mrd. | |
+8,09 % | 207 Mrd. | |
-5,77 % | 205 Mrd. | |
+6,19 % | 164 Mrd. |